Integrated proteogenomic characterization of glioblastoma evolution

Kyung Hee Kim, Simona Migliozzi, Harim Koo, Jun Hee Hong, Seung Min Park, Sooheon Kim, Hyung Joon Kwon, Seokjun Ha, Luciano Garofano, Young Taek Oh, Fulvio D'Angelo, Chan Il Kim, Seongsoo Kim, Ji Yoon Lee, Jiwon Kim, Jisoo Hong, Eun Hae Jang, Bertrand Mathon, Anna Luisa Di Stefano, Franck BielleAlice Laurenge, Alexey I. Nesvizhskii, Eun Mi Hur, Jinlong Yin, Bingyang Shi, Youngwook Kim, Kyung Sub Moon, Jeong Taik Kwon, Shin Heon Lee, Seung Hoon Lee, Ho Shin Gwak, Anna Lasorella, Heon Yoo, Marc Sanson, Jason K. Sa, Chul Kee Park, Do Hyun Nam, Antonio Iavarone, Jong Bae Park

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The evolutionary trajectory of glioblastoma (GBM) is a multifaceted biological process that extends beyond genetic alterations alone. Here, we perform an integrative proteogenomic analysis of 123 longitudinal glioblastoma pairs and identify a highly proliferative cellular state at diagnosis and replacement by activation of neuronal transition and synaptogenic pathways in recurrent tumors. Proteomic and phosphoproteomic analyses reveal that the molecular transition to neuronal state at recurrence is marked by post-translational activation of the wingless-related integration site (WNT)/ planar cell polarity (PCP) signaling pathway and BRAF protein kinase. Consistently, multi-omic analysis of patient-derived xenograft (PDX) models mirror similar patterns of evolutionary trajectory. Inhibition of B-raf proto-oncogene (BRAF) kinase impairs both neuronal transition and migration capability of recurrent tumor cells, phenotypic hallmarks of post-therapy progression. Combinatorial treatment of temozolomide (TMZ) with BRAF inhibitor, vemurafenib, significantly extends the survival of PDX models. This study provides comprehensive insights into the biological mechanisms of glioblastoma evolution and treatment resistance, highlighting promising therapeutic strategies for clinical intervention.

Original languageEnglish
Pages (from-to)358-377.e8
JournalCancer Cell
Volume42
Issue number3
DOIs
Publication statusPublished - 2024 Mar 11

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Inc.

Keywords

  • BRAF
  • longitudinal glioblastoma
  • neuronal
  • proteogenomics
  • recurrence
  • synapse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Integrated proteogenomic characterization of glioblastoma evolution'. Together they form a unique fingerprint.

Cite this